Technology | Image Guided Radiation Therapy (IGRT) | June 30, 2016

Accuray Receives FDA Clearance for Radixact Image-Guided Radiation Therapy Platform

Next-generation "smart" system features more powerful linear accelerator, megavoltage CT imaging and helical treatment delivery for highly precise treatments

Accuray, Radixact Treatment Delivery Platform, image-guided radiation therapy, IGRT, FDA clearance

June 30, 2016 — Accuray Inc. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Radixact Treatment Delivery Platform for radiation therapy. Accuray also received 510(k) clearance for its new treatment planning and data management systems, Accuray Precision Treatment Planning System and iDMS Data Management System.

These next-generation hardware and software solutions, which together make up the new Radixact system, enable faster, more efficient delivery of extremely precise treatment to a wider range of cancer patients, including those undergoing retreatment.

The system features a more powerful linear accelerator, megavoltage computed tomography (MVCT) imaging and helical treatment delivery, so clinicians can apply highly conformal and homogenous dose distributions to any target volume while precisely sparing normal healthy tissue during each treatment fraction. The new Accuray Precision Treatment Planning System with smart, automated workflows and midcourse decision-making tools enables clinicians to adapt delivery to changes in tumor size, shape and location within the patient.

According to Jennifer Smilowitz, Ph.D., clinical associate professor University of Wisconsin School of Medicine and Public Health, who was involved in the development of the new radiation therapy technology, "The Radixact System builds upon the unique strengths of the TomoTherapy platform. Expanded delivery capabilities enable treatment with image-guided, intensity-modulated radiation therapy (IG-IMRT), an extremely accurate form of radiation therapy) to an expanded range of patients. New database features make the ring gantry-based system even easier to operate and integrate within a radiation oncology department."

Accuray will initiate commercial release of the Radixact System late in the first quarter of fiscal year 2017 (July - September 2016).

For more information: www.accuray.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more